Prokidney Corp reports results for the quarter ended September 30 - Earnings Summary

Prokidney

12/11/2026 23:12

Prokidney Corp PROK.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of six analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -17 cents to -12 cents per share.
Revenue fell 19.8% to $174.00 thousand from a year ago; analysts expected $124.60 thousand. 
Prokidney Corp's reported EPS for the quarter was a loss of 17 cents​.
The company reported a quarterly loss of $35.59 million.
Prokidney Corp shares had fallen by 31.9% this quarter and lost 49.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Prokidney Corp is $7.00, about 83.6% above its last closing price of $1.15
This summary was machine generated from LSEG data November 12 at 11:12 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.14
-0.17
Missed
Jun. 30 2026 
-0.14
-0.15
Missed
Mar. 31 2026 
-0.14
-0.14
Met
Dec. 31 2025 
-0.12
-0.14
Missed